H.C. Wainwright reiterates Buy rating on Medicenna stock with $2.50 target

H.C. Wainwright reiterated a Buy rating and $2.50 price target for Medicenna Therapeutics (MDNA), reinforcing a Strong Buy consensus and significant upside from its current $0.61 trading price. The clinical-stage immunotherapy company expects to release clinical data updates for its lead asset, MDNA11, from its Phase 1/2 ABILITY-1 study before year-end, with top-line data anticipated by Q4 2025. While Medicenna boasts a strong current ratio and more cash than debt, rapid cash burn and the need for future funding, particularly for its planned MDNA113 program, remain key financial considerations for investors.

Analysis

H.C. Wainwright's reiterated Buy rating and $2.50 price target for Medicenna Therapeutics (MDNA) highlight a substantial valuation gap compared to its current $0.61 share price, a sentiment echoed by a broader analyst consensus with price targets ranging up to $3.63. The company's near-term valuation is heavily dependent on its lead asset, MDNA11, with significant catalysts approaching. Management expects to release clinical data updates from the Phase 1/2 ABILITY-1 study in one or two disclosures before year-end, which will be a critical test of the drug's potential in both monotherapy and combination settings. While the company's balance sheet appears robust in the short term, holding more cash than debt and featuring a strong current ratio of 4.94x, this is offset by a rapid cash burn rate. This financial pressure is a key risk factor, particularly as the advancement of its next pipeline candidate, MDNA113, into clinical trials in 2026 is explicitly contingent upon securing additional funding.

Key Decisions for Investors

• Investors should recognize Medicenna as a high-risk, catalyst-driven investment where the significant upside implied by analyst targets is contingent on positive clinical data from the upcoming MDNA11 updates.
• Careful monitoring of the company's cash burn rate and balance sheet is essential, as the need for future financing to support the pipeline, including the MDNA113 program, introduces a material risk of shareholder dilution.
• The one or two clinical data disclosures for the ABILITY-1 study expected before year-end are the most critical near-term events, and positions should be managed according to an investor's risk tolerance for binary clinical outcomes.